"Giving voice to the needs of the German Medical Marijuana/Cannabis Patient Community" / Cenedella, Patient Advocate since 1977.

1 Comment

GERMAN PATIENT ROUNDTABLE announces Educational event scheduled for Oct. 19th in Berlin.

The cannabis patient Consultation  – information Evening (Part 1) 

“Where can I find reliable information about” Medical cannabis “? My previous medications have hardly any effect and sometimes strong side effects. What can I do as a patient? “

Cannabis as a medicine is gaining more and more acceptance in our society. Nevertheless, obtaining this prescriptive medicine is still associated with some bureaucratic and reputational hurdles. Stigma and social prejudice make doctors shy away and potential patients remain helpless. The German Patient Roundtable brings together the various stakeholders, provides active assistance and promotes dialogue between patients, doctors, research and industry.

The aim of the German Patient Roundtable is to bring together, network and inform patient interests in order to optimally care for them. Through active action, the above-mentioned hurdles should be eliminated and more patients should be informed about the possibility of treatment with cannabinoids.

The event on October 19th highlights cannabis as a medicine and provides helpful information, especially for (potential) patients. The symposium looks at four perspectives:

1. Advocacy: People who are committed to patients.

2. Science: People who are researching and actively working on cannabinoids.

3. Medicine: people who actively treat with cannabinoids in medical practice.

4. Patients: People who want to be treated or are treated with “Medical Cannabis”.

This event is the first in a presumably four-part series of events. The second appointment is planned for January 18th 2019.

*: The event is an information evening. There is no medical consultation (by doctors)


MORE INFO AT:    Oct. 19th event

Leave a comment

Germany Model Cannabis Model Projects coming to a town near you soon – HanfJournal

Der Vorsitzende des Gesundheitsausschusses wirbt jetzt für Cannabismodellprojekte

Even though the CDU / CSU parliamentary group can hardly be described as an advanced party in debates on the subject of cannabis and because of the statements made by its drug commissioners for the second time in office, not all the politicians of the Union have stood on the wrong track. Obviously, some people in the conservative camp, despite the prevailing mood in their ranks, independently deal with the ongoing upheavals in global drug policy and do not shy away from the presentable results. After the health politician Erwin Rüddel Uruguay visited, finally changed his opinion on the approach in this country. The chairman of the Health Committee is now promoting cannabis model projects.


” I came there with hesitation and very thoughtful, ” said Rüddel the Stuttgart news in retrospect on his trip to Uruguay,which gave him the impetus for the now required care attempt in cannabis model projects. Since the legalization of cannabis in the South American country would have virtually dried up the black market, but where it still existed to concentrate on particularly strong varieties of intoxicating hemp plants, one would now have to make model tests in their own and the local circumstances Gather data that would finally bring progress to the deadlocked debate. According to Rüddel, pharmacies should be allowed to give cannabis to persons over the age of 18 who have previously registered as participants in the scientific model experiment in order to obtain usable results.To clarify the extent to which a more liberal drug policy could have an impact on society . With facts gained in this way one would finally have some instruments to objectify the entire and often emotionally led discussion something, is the CDU health politician Erwin Rüddel sure. However, the Chairman of the Federal Health Committee Rüddel currently receives even less from his own party comrades than from other political camps, where the change of heart is immediately strongly supported and hopes for rapid progress.


In times when synthetic cannabinoids can cost a human life , safe alternatives to prohibition should be seriously considered.

Leave a comment

ONLINE CANNABIS COMPANY PRESENTATIONS LIVE: September 12, 2018 First Presentation begins at 10:00am ET Please join us Wednesday, September 12th for live presentations from CEOs and top executives from the cannabis companies listed below. Attendees will be able to ask the speaker questions in real-time and visit the virtual “exhibit hall” to view or download investor kits, annual reports, and interact with other investors.;F:BS!6060&DDHUUID=D957F827-80E7-4629-B975-7E5799F66AE4


The companies below will be presenting at our next event. Click the “Add to Calendar” button for any presentations you’d like to attend in order to setup a reminder.

10:00am ET
LiveWell Canada Inc.
David Rendimonti, President
Add to Calendar
10:30am ET
Medicine Man Technologies Inc. 
Brett Roper, Co-Founder and Chief Executive Officer
Add to Calendar
11:00am ET
KushCo Holdings, Inc.
Jim McCormick, Chief Financial Officer & Chief Operating Officer
Add to Calendar
11:30am ET
Presenting Company Logo
iAnthus Capital Holdings, Inc.
Hadley Ford, Chief Executive Officer

Add to Calendar
12:00pm ET
Presenting Company Logo
Aurora Cannabis Inc.
Cam Battley, Chief Corporate Officer

Add to Calendar
12:30pm ET
Presenting Company Logo
Golden Leaf Holdings Ltd.
William Simpson, Chief Executive Officer

Add to Calendar
1:00pm ET
Presenting Company Logo
Terra Tech Corp.
Derek Peterson, Chairman and Chief Executive Officer

Add to Calendar
1:30pm ET
Presenting Company Logo
CordovaCann Corp.
Taz Turner, Chairman & Chief Executive Officer

Add to Calendar
2:00pm ET
Presenting Company Logo
Khiron Life Sciences Corp.
Chris Naprawa, President

Add to Calendar
2:30pm ET
Presenting Company Logo
The Green Organic Dutchman Holdings Ltd.
Danny Brody, Vice President – Investor Relations
Add to Calendar
3:00pm ET
Presenting Company Logo
MPX Bioceutical Corp.
Beth Stavola, Chief Operating Officer

Add to Calendar
October 4 Monthly Conference
November 14 and 15 Deutsche Bank Partner Event
December 6 Monthly Conference


Leave a comment

In a telephone conversation with the Dutch health Minister Hugo de Jonge, the German counterpart and CDU politician Jens Spahn is said to have acted to ensure that the supply bottlenecks in the field of marijuana…

Because cannabis patients are not allowed to grow their own natural medicine in the garden or in tents, health insurance companies, pharmacies and importers need to work closely together so that the prescribed medicine is actually available when needed. However, as the need for the nearly side-effect free medicinal plant is much greater than originally expected from cannabis for medical-releasing government, the costly imports of medicinal hemp are in no way sufficient for the ever-growing patient base. In order for the delayed future of cannabis cultivation in Germany not to affect other sick people, the government has now acted and requested twice the amount of grass from the Netherlands.

Doppelte Menge Gras aus den Niederlanden angefordert

In a telephone conversation with the Dutch health Minister Hugo de Jonge, the German counterpart and CDU politician Jens Spahn is said to have acted to ensure that the supply bottlenecks in the field of marijuana are not quite as strong. Of the originally planned 700 kilograms of Dutch medicinal hemps, more than twice the amount has been increased, so now thanks to the commitment of Hugo de Jonge with an amount of up to 1500 kilos of marijuana in German pharmacies calculated annuallycan be. The 1.5 tons are needed because a mistake in the bidding process of the BfArM cannabis agency ensured that it was not possible in court to distribute licenses for the cultivation of cannabis in a timely manner. Because it is not until 2020 at the earliest in the harvest of marijuana produced in this country can be expected, the federal government must increase the import quantities of coveted medicine accordingly . Federal Minister of Health Jens Spahn called the verbally closed trade a ” lived neighborhood ” and emphasized that the Netherlands “made an important contribution to the medical treatment of German patients “.


Why in the neighboring country, however , enjoyment consumption for decades no major problem for public life and why from the moment of acquiescence no bottlenecks more emerge in the supply routes in the medical sector , the CDU politician but would rather not from his Dutch counterpart in conversation explain. As far as the friendship goes then apparently not again – and you pay eventually also voluntarily with cash for their own inability; but certainly not for teachings.



Leave a comment

U N I T Y – by Hezekiah D. Allen

In order to achieve this grand aspiration of unification, I think we need to change the way we treat each other.

There are a few lessons that I have learned over the last few years that I think may be of value as we embark on this grand project:

  1. Talk to each other, not about each other. If you find yourself talking about someone in our community, give them a call. If you don’t know them that well, maybe try stick to facts and not spread rumors. Gossip doesn’t help.
  2. Talk less and listen more.  
  3. Stay focused. Care less what people say and be more careful with what you say.
  4. Take good care of yourself. Smile more. Breathe more deeply. Drink more water.
  5. How you deliver your message matters as much as your message.Don’t discredit yourself by being unprofessional. If you start reacting and losing your cool or losing your focus, please review and repeat lesson #4.

—-> Speak up on the regulationsPublic comment period ends on Monday.

We have drafted a few template letters on important issues to help you get started. Please click on the links to download the following:

I am sure you will hear from me soon! I really hope to see you next month so please register for the event and make hotel registrations.

With love and gratitude,


Hezekiah D. Allen

Leave a comment

The United Nations will conduct a first-ever review of its cannabis ban

A decision by the United Nations could instigate a review of cannabis scheduling in the United States. The United Nations has announced that it will conduct a critical review of cannabis to determine whether it should continue to be banned under international law, Marijuana Moment reports. The review, which is expected to begin in November, will be conducted by the World Health Organization’s Expert Committee on Drug Dependence (ECDD) which makes recommendations to the UN regarding internationally prohibited substances.

Source: The United Nations will conduct a first-ever review of its cannabis ban

Leave a comment

German cannabis lawyer KFN+ with good update on the German Cannabis As Medicine Cultivation, revised bid.

After the first award procedure for the cultivation of medical cannabis in Germany had been banned by the Higher Regional Court of Düsseldorf now the time has finally come and the Cannabis Agency has published the details of the new award procedure.

The Federal Republic of Germany, represented by the Federal Institute for Drugs and Medical Devices (BfArM) and the Cannabis Agency, continues to be the contracting authority for the award procedure for the cultivation, further processing, storage, packaging and supply of cannabis for medical purposes. This concerns the award of a public contract by way of an open procedure in accordance with §§ 97 et seqq. GWB (German Act against Restraint of Competition) and § 15 VgV (Regulations on the Award of Public Contracts and Procedures).

Prospective parties must prove their economic and financial capacity of the last 3 years when filing an application. Information must also be provided on sales in the cultivation, processing and supply of cannabis for medical purposes (THC content ≥ 1%) for the last 3 financial years, if available. Turnover in the cultivation, supply and processing of medicinal plants which have been placed on the market as medicinal products or active agents in a medicinal product after processing may also be considered as commendation now. The minimum condition for affirming suitability is then at least one cannabis reference for the cultivation of medical cannabis or one cultivation and processing reference for medicinal plants. The services provided must have been performed in accordance with both the GACP standard (Good Agricultural and Collection Practice) and the GMP standard (Good Manufacturing Standards), i.e. in accordance with the „Eudralex: Volume 4 Medicinal Products for Human and Veterany Use and Annex 7: Manufacture of Herbal Medicinal Products“, whereby approval for the manufacture of medicinal products must have been obtained from the competent authority ex ante.

If the contract is awarded Information must also be provided on how the financing of the contract is secured, and that the named land plot is available for the production site.

With regard to economic, financial, technical and professional capacity, a bidder may make use of the capacities of other companies within the framework of the so-called qualification hire. Thus, bidding consortia are also permitted, where the minimum conditions set must be fulfilled by at least one member of the bidding consortia.

The services are awarded by lot. The delivery quantity per batch is 200 kg per year. The following lots are set up:

Lot 1 to lot 8: cannabis flowers type 1

Lot 9 to lot 11: cannabis flowers type 2

Lot 12 and lot 13: cannabis flowers type 3

The cannabis flowers to be delivered must – depending on type respectively lot – contain the following concentration of tetrahydrocannabinol (THC) and cannabidiol (CBD):

type 1 with definition: THC between 18 and 22%, CBD < 1%

type 2 with definition: THC between 12 and 16%, CBD < 1%

type 3 with definition: THC between 5 and 9%, CBD between 5 and 9%.

Bidders may submit tenders for all lots, whereby one bidder may receive a maximum of 5 lots.

The delivery shall cover the following periods and quantities in total:

Delivery schedule of total quantity for the defined types

  1. Delivery year 2600 kg (type 1 1600 kg, type 2 600 kg, type 3  400 kg)
  2. Delivery year 2600 kg (type 1 1600 kg, type 2 600 kg, type 3  400 kg)
  3. Delivery year 2600 kg (type 1 1600 kg, type 2 600 kg, type 3  400 kg)
  4. Delivery year 2600 kg (type 1 1600 kg, type 2 600 kg, type 3  400 kg)

The award criteria are determined by a scoring system. The bidder with the lowest price offer for medical cannabis in the specified quality (detailed in euros per gram) receives 40 points. Another maximum of 5 points can be achieved by the quality of:

– the concept of technical facilities of the plant,

– the structural standards,

– the concept for GACP and GMP- standard,

– the concepts for cultivation, processing and delivery (e.g. with regard to prevention of failed harvests),

– the concept for production cycles,

– the concept for selection and training of personnel,

– safety and security concept.

When bidding, a concept for scheduling in the starting phase up to the first harvest with the respective intermediate steps must be submitted. The concept of the site and production must be described in detail for all stages to enable the cannabis agency to evaluate the award criteria. The origin and characteristics of the seed or plant material used must also be described in detail. The crucial technical facilities must also be particularised in concrete terms.

At the time of purchase capacity, the cannabis flowers must be appropriate for medical use. They must comply with the legal requirements of the current monography for cannabis flowers of the German Pharmacopoeia and the European Pharmacopoeia. With regard to heavy metal contamination certain limit values must be satisfied. The cultivation must also have been carried out according to the currently valid European GACP and GMP standards (see above) of course.

Conclusion: the new tender procedure slightly increases the quantities to be produced, which of course constitutes improvement. A cultivation and processing reference for medicinal plants is also sufficient to meet the minimum requirements. The quantities put out to tender however are still so meagre that it remains in doubt whether or not the production of medical cannabis in Germany can actually be of economic interest to interested companies. In view of the already approved import quantities of 21 tonnes in 2018 and a further increase in demand it remains cloudy why the German Federal Government is blocking the production of medical cannabis in their own country by tendering out such small quantities rather than giving a new and emerging industry in the country a chance.